Personal genetics company 23andMe has raised $115 million in a Series E funding led by Fidelity Management & Research Company, with participation from new investors Casdin Capital, WuXi Healthcare Ventures and Xfund; as well as existing investors – Illumina (ILMN), New Enterprise Associates, MPM Capital, and Google Ventures. The new capital will allow the company to expand its operations and maximize the potential of its direct-to-consumer product in the US and elsewhere. 23andMe expects to launch a new user experience that includes carrier status reports in the US, among other things. Also, the company plans to procure new laboratory space for therapeutic research, a next generation sequencing laboratory as well as other investments in long-term growth.
“23andMe pioneered the personal genetics industry,” said Andy Page, president of 23andMe. “Our efforts to enable individuals to access, understand and benefit from the human genome have achieved a level of scale that will enable us to further advance genetic research and drug discovery around the world.”
23andMe was the first company to receive market authorization from the FDA for a direct-to-consumer genetic test (Bloom Syndrome test). Beyond the US, it also offers DNA tests in the UK, Canada and certain EU countries.